Ticker: XBIT

XBiotech Inc. (NASDAQ: XBIT) - Q2 2025 brief What's happening inside: management cut clinical activity and operating costs in H1 2025, repaid a $10.0 million related-party convertible loan, and recognized significant non‑cash share‑based compensation tied to executive awards. The company remains ...

XBiotech Inc. (NASDAQ: XBIT) recently released its Q1 2025 financial results, revealing both progress and ongoing challenges within the company. Key Points from the Income Statement: Net Loss: Reported at $10.9 million for Q1 2025 compared to $10.0 million for the same period in 2024, reflecting...